Semustine

Semustine
Clinical data
ATC code	L01AD03 (WHO) ;
Identifiers
	IUPAC name 1-(2-Chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea;
CAS Number	13909-09-6 ;
PubChem CID	5198;
ChemSpider	5009 ;
UNII	6YY7T1T567;
KEGG	D05822 ;
ChEBI	CHEBI:6863 ;
CompTox Dashboard (EPA)	DTXSID8031603 ;
ECHA InfoCard	100.162.271
Chemical and physical data
Formula	C10H18ClN3O2
Molar mass	247.72 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1CCC(CC1)NC(=O)N(CCCl)N=O;
	InChI InChI=1S/C10H18ClN3O2/c1-8-2-4-9(5-3-8)12-10(15)14(13-16)7-6-11/h8-9H,2-7H2,1H3,(H,12,15) ; Key:FVLVBPDQNARYJU-UHFFFAOYSA-N ;
	(what is this?) (verify)

Semustine (1- (2-Chloroethyl)-3-(trans-4-methylcyclohexyl)- 1-nitrosourea, MeCCNU) is an alkylating nitrosourea compound used in chemotherapy treatment of various types of tumours. Due to its lipophilic property, semustine can cross the blood-brain barrier for the chemotherapy of brain tumours, where it interferes with DNA replication in the rapidly-dividing tumour cells. Semustine, just as lomustine, is administered orally. Evidence has been found that treatment with semustine can cause acute leukaemia as a delayed effect in very rare cases.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.